Solganick & Co.

OCTOBER 6, 2023

Business Valuation: Understand and obtain a professional valuation or estimate to understand the worth of your technology business. Running a compresensive and targeted M&A auction process will help to maximize the outcome including receiving multiple offers and driving valuation higher.

Sale 52

Sale Business Valuation M&A 52

Software Equity Group

MARCH 26, 2024

Main Capital has made 215 total investments since its founding, with current assets under management (AUM) of $2.37B and an active portfolio of 47 firms, with a median valuation of $10.25M. Thoma Bravo maintains an active portfolio of 76 firms, with $134B in AUM and a $435M median valuation. The firm currently employs 31 professionals.

Private Equity 52

Private Equity Equities Investment Portfolio 52

Devensoft

JUNE 20, 2023

These elements include identifying potential targets, assessing the value of these targets, conducting due diligence, negotiating, and closing deals, and post-merger integration and management. Valuation methods can include discounted cash flow analysis, comparable company analysis, and precedent transaction analysis.

M&A 52

M&A Corporation Mergers and Acquisitions Mergers 52

MergersCorp M&A International

JANUARY 25, 2024

TSI is anchored by Turn Capital, the single-family office of Singaporean entrepreneur Joseph Phua, who established himself within Asia’s technology media and entertainment arena through multiple successful acquisition and investment deals in the region.

Investment 52

Investment M&A Mergers and Acquisitions Capital 52

Cooley M&A

JULY 9, 2021

However, the Chancery Court’s most recent appraisal decision, In Re Appraisal of Regal Entertainment Group (Del. The Regal appraisal proceeding arose from Cineworld’s acquisition of Regal Entertainment Group in February 2018. Selected Appraisal Decisions Since Aruba Using Valuation Method Other than Deal Price.

Mergers and Acquisitions 52

Mergers and Acquisitions Sale Shares Entertainment 52

Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. The need for big pharma to fill looming revenue gaps as medicines lose marketing exclusivity is balanced against increasing caution in boardrooms about making large, risky bets.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40